Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.65 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18421667 | 1.00 | HCAR2 (0.65) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL2609731 | 0.89 | HCAR2 (0.52) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL2609729 | 0.88 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL20830052 | 0.87 | HCAR2 (0.54) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL13133177 | 0.85 | HCAR2 (0.67) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL13133179 | 0.85 | HCAR2 (0.67) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL6446896 | 0.85 | HCAR2 (0.67) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL28625721 | 0.83 | HCAR2 (0.45) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL2609725 | 0.83 | HCAR2 (0.45) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 | |
| SCHEMBL7262707 | 0.83 | HCAR2 (0.62) | HCAR2NFE2L2KEAP1GFPT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131633-B1 | MMF-DERIVATIVES OF ETHYLENEGLYCOLS | ALBRECHT WOLFGANG (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-9969674-B2 | MMF-derivatives of ethyleneglycols | RATIOPHARM GMBH (DE) | 2018-05-15 | — | — | US | disclosed |
| US-20180000770-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170368013-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3131633-A1 | MMF-DERIVATIVES OF ETHYLENEGLYCOLS | ratiopharm GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-20170029357-A1 | MMF-DERIVATIVES OF ETHYLENEGLYCOLS | ALBRECHT, WOLFGANG (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2016153957-A2 | METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF FUMARATES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | BIOGEN MA INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885NFE2L2 2133/4885KEAP1 2571/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | HCAR2 68/4885NFE2L2 2036/4885KEAP1 2596/4885 |
| US-20170368013-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | HCAR2 1264/4885NFE2L2 2166/4885KEAP1 1718/4885 |
| US-20180000770-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | HCAR2 1264/4885NFE2L2 2166/4885KEAP1 1718/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885NFE2L2 2133/4885KEAP1 2571/4885 |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | HCAR2 1264/4885NFE2L2 2166/4885KEAP1 1718/4885 |
| US-20170029357-A1 | MMF-DERIVATIVES OF ETHYLENEGLYCOLS | MGMT, PMM2, HLA-DRB1 | HCAR2 455/4885NFE2L2 184/4885KEAP1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.